Common Contracts
1 similar Exclusive Licensing Agreement contracts
Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®Exclusive Licensing Agreement • August 18th, 2021
BAD VILBEL, Germany and LAVAL, Québec, Canada – August 18, 2021 – Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, and STADA MENA DWC-LLC (“STADA”), a subsidiary of STADA Arzneimittel AG, a specialty pharma, generics and consumer healthcare group, today announced an exclusive commercialization and development license agreement (the “Agreement”) for the exclusive rights to the topical anaesthetic cream Pliaglis®, in 15 countries in the Middle East and North Africa (“MENA”) region, comprising: Saudi Arabia, the United Arab Emirates (“UAE”), Kuwait, Oman, Qatar, Bahrain, Jordan, Lebanon, Egypt, Algeria, Morocco, Tunisia, Iraq, Libya and Yemen (the “Territories”).
